# Afternoon Agentic Swing Scan — No Trade

- Timestamp: 2026-08-17T17:32:12Z
- Account: Robinhood Agentic ••••1041 (433711041)
- Mode: pre-authorized autonomous equities-only operation
- Policy: ACTIVE; policy file loaded. No date-specific trading plan found.

## Broker and risk state

- Account active, cash type, agentic_allowed=true.
- Portfolio value: $329.3724; kill switch ($10) not triggered.
- Equity value: $259.5824; broker cash: $69.79; authoritative spendable buying power: $32.11.
- Unsettled sale proceeds: $37.68 (excluded from buying power).
- Open-ish equity orders checked independently: new, queued, confirmed, unconfirmed, partially_filled — none.
- Recent fill: AVGO sell 0.095750 shares at $393.5001 on 2026-08-17 13:37:43Z.
- Daily drawdown gate: not triggered by available live state; portfolio remains above starting capital and current positions mark net positive versus average cost.

## Positions and management

Quotes as of approximately 17:31:34Z.

| Symbol | Qty | Avg cost | Mark | Value | Unrealized | Decision | Invalidation / target |
|---|---:|---:|---:|---:|---:|---|---|
| BAC | 1.046363 | $62.12 | $64.655 | $67.65 | +$2.65 (+4.08%) | HOLD (strongest) | Review/exit below $62.90; target $67.00 then $69.00 |
| SHOP | 0.862075 | $144.09 | $148.30 | $127.85 | +$3.63 (+2.92%) | HOLD, no add | Review/exit below $142.00 earnings-gap support; target $158.50 then $165 |
| MA | 0.113541 | $572.48 | $563.63 | $64.00 | -$1.00 (-1.55%) | HOLD but weakest | Review/exit below $552; target $583 then $600 |

No averaging down, stop widening, trim, exit, or rotation executed. SHOP's -3.90% session requires monitoring but remains above the $142 earnings-gap support. MA is below cost but above rising SMA20 (~$559.40 from completed daily bars) and remains inside its technical risk band. BAC is near a 52-week high ($65.225 intraday) with improving quarterly revenue/net income, but no add was made because the original scale-in plan was unavailable and the financial sector ETF was down intraday.

## Regime

Classification: **mixed/rotation, long-term risk-on trend**.

- SPY $773.505 (-0.37%), QQQ $729.92 (-0.16%), IWM $303.605 (-0.49%) intraday; each remains above its completed-bar SMA20 and SMA50.
- Leading intraday sectors: energy XLE +0.93%, industrials XLI +0.35%, technology XLK +0.28%. Lagging: consumer discretionary XLY -1.35%, financials XLF -0.47%.
- Recent earnings breadth is strong, but rate-hike odds and upcoming FOMC minutes/retail earnings create event risk. VIX was reported near 14.5, implying low hedging demand and possible complacency.

## Broad scan and ranked fresh candidates

The Robinhood Daily Movers universe was screened live; quote/liquidity checks rejected OTC/wide-spread and sub-$5 names. Rankings use the policy's 16-point framework.

1. **AXTI — 11/16, WATCH / reduced-size only after retest.** $96.54 (+18.25%); $96.43/$96.59 spread; 9.75M shares traded vs 11.56M 30-day average by 17:31Z. Catalyst: Q2 revenue +164% YoY to $47.6M, record InP demand tied to AI optical connectivity, upward estimate revisions. Technical: reclaimed ~$90.30 resistance but is extended after a large one-day move; prefer a successful retest of $90–92. Invalidation $84.50; targets $105/$112. No entry because chasing violates the ~1 ATR extension rule.
2. **CBRS — 10/16, WATCH.** $254.87 (+16.39%); 11.56M volume vs 6.37M 30-day average. AI demand and $25.4B reported remaining performance obligations support the thesis, but the company remains loss-making (negative P/E), Q2 had a revenue miss, and today's reversal follows a volatile post-earnings period. Require consolidation/retest near $240–245; invalidation $223; targets $275/$300.
3. **ARGX — 10/16, WATCH.** $989.225 (+16.20%), new 52-week high; 431k volume vs 281k average. Quality is better (positive P/E ~30.7; strong immunology franchise), but no verified same-day fundamental catalyst was found and the price is a first-day vertical gap. Require a multi-session hold/retest near $930–950; invalidation $900; target $1,050.
4. **CAPR — 8/16, NO TRADE.** $7.44 (+11.88%) with high liquidity, but clinical-stage, loss-making biotech and no verified catalyst in this scan. High binary risk and unclear durable invalidation.
5. **VCX — 8/16, NO TRADE.** $38.18 (+10.99%), strong relative volume, but intraday range $32.78–$40.88 and unusual closed-end-fund structure make risk/price discovery unsuitable.

Rejected examples: FSRCY, KYSEY, CHFFY, KGDEY, PAFRY, LMPMY and BUUU for extreme illiquidity/wide spreads; HIVE/ENVX/ENHA/EYPT for price below $5 and/or deteriorating speculative structure; BALY and ABXXF for breakdowns.

## Deployment decision

- Available liquid buying power after pending orders: $32.11.
- Policy 80% deployment target if a setup qualifies: $25.688.
- Required reserve: $6.422.
- New cash deployed this scan: $0.00.
- Spendable reserve retained: $32.11.
- Existing marked equity exposure: approximately $259.49, or 78.78% of total account value.

**Decision: no new trade.** Existing gross exposure is already near the portfolio-level 80% objective, while every fresh mover either lacked a verified catalyst, was extended beyond a prudent retest entry, was speculative/loss-making, or failed liquidity/price rules. Spending 80% of current buying power would have forced a low-quality fourth holding and violated the no-chasing/no-forced-trade gates.

## Actions and failures

- Order previews: none; no candidate reached entry criteria.
- Orders placed/cancelled: none.
- Exact fills from this scan: none.
- Tool issue: one malformed internal tool invocation occurred and returned an error before any broker action; no account impact.
- Historical benchmark payload was normalized programmatically and compact SMA/ATR/momentum fields were computed successfully.
